-6.94%
Today
Loading 1D prices…
Company profile
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Houston, TX, United States
Employees
15
Fiscal year end
1231
CIK
1958777
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| LNAILunai Bioworks Inc. Common Stock | $10.8M | $20.9K | -7409.88% | -$0.07 | -2.26% | Unrated |
| AZTRAzitra Inc Common Stock | $10.8M | $0.00 | — | -$2.25 | -1.11% | Buy |
| VTGNVistagen Therapeutics Inc. Common Stock | $10.5M | $1.3M | -5491.88% | -$1.83 | 0.00% | Hold |
| MTVAMetaVia Inc. Common Stock | $10.9M | $0.00 | — | -$7.35 | -5.14% | Buy |
| KALAKALA BIO Inc. Common Stock | $11.1M | $0.00 | — | -$3.31 | +1.60% | Unrated |